USA Gilmore O’Neill, CEO of Editas Medicine, reflects on the company’s evolution from CRISPR pioneer to focused in vivo therapeutics developer. Two years into a strategic pivot, O’Neill shares the reasoning behind discontinuing the reni-cel cell therapy program in favor of lipid nanoparticle-delivered gene editing, and how EDIT-401, targeting severe hyperlipidemia,…
Europe Childhood cancer survival rates in high-income countries now exceed 80 percent, but that masks a more uneven picture: paediatric drug development lags far behind adult oncology, follow-up and psychosocial care remain patchy across Europe, and survivors can face life-altering side effects that surface decades after treatment ends. Carina Schneider and…
Korea Vaxcellbio aims to become a genuine game changer in the global immune cell therapy market Dr Je-Jung Lee, CEO of Vaxcellbio, discusses how his experience as a physician and immunotherapy researcher shaped the company’s patient-centred mission. He outlines Vaxcellbio’s differentiated NK cell, CAR-T and CAR-MIL platforms, manufacturing strategy, Korea’s evolving…
USA Legend is looking at all ways to bring CAR-T to more patients, including allogeneic, autologous, and in vivo approaches Alan Bash, Interim CEO of Legend Biotech speaks about achieving the milestone of treating 13,000 adult patients, with relapsed or refractory multiple myeloma who have received at least 1 prior line…
MEA After years of foundational investment in genomics, population screening, and rare disease diagnostics, Gulf nations are entering a transformative era: the delivery of advanced therapeutics. The cell and gene therapy (CGT) landscape within the GCC has fundamentally shifted from importing foreign cures to establishing localized, highly sophisticated manufacturing and clinical…
China Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord injury, MSA and ALS have remained among the most difficult conditions to treat, with available therapies largely focused on managing…
South Korea There is a real sense of energy and ambition across the Korean biopharma industry Sungphil Kim, General Manager of Cytiva Korea, discusses his vision for strengthening Korea’s biopharma ecosystem through customer-centricity, talent development and innovation. He highlights Cytiva’s Songdo hub, support for advanced therapies, AI and automation, and practical training…
Korea Korea is a highly developed and extraordinarily fast-moving market; you simply cannot afford to lag behind Marc Franck, Managing Director of Zuellig Pharma Korea, explains why Korea has become one of the company’s most strategic markets, driven by clinical trials, biologics and advanced logistics. He discusses investments in automation, the…
Taiwan In recent years, Taiwan’s policymakers have been aggressively deploying a multi-layered industrial strategy – and doing so with the benefit of watching earlier regional movers stumble – in an effort to transform the island into a premier global hub for Cell and Gene Therapy (C>) manufacturing and development. This state-driven…
Taiwan Semiconductors: Silicon Powerhouse Taiwan and semiconductors – the microscopic chips inside virtually every electronic device – are inextricably linked. For a modestly sized island, Taiwan’s semiconductor dominance is extraordinary: through the state-backed TSMC (Taiwan Semiconductor Manufacturing Company), the island functions as the world’s foundry, manufacturing the advanced chips designed by…
GCC Healthcare transformation across the GCC is entering a new phase, driven by major investments in precision medicine, genomics, and healthcare system modernisation, with countries such as Saudi Arabia and the UAE positioning themselves at the forefront of global healthcare innovation. Against this backdrop, Bristol Myers Squibb is expanding its role…
Korea Seong-Wook Lee, CEO and founder of Rznomics, has spent more than two decades advancing trans-splicing ribozyme (TSR) technology as a novel RNA editing platform. After nearly 20 years in academia, he founded Rznomics to translate the approach into therapies for genetic and intractable diseases. With FDA-cleared clinical programmes, strategic partnerships,…
See our Cookie Privacy Policy Here
